Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.64 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.64 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.58 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.58 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.58 |
| ▸ | SRC | P12931 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL436189 | 0.91 | EGFR (0.75) | EGFRERBB2ERBB4SRC | |
| SCHEMBL29838794 | 0.91 | EGFR (0.75) | EGFRERBB2ERBB4SRC | |
| SCHEMBL29779503 | 0.91 | EGFR (0.75) | EGFRERBB2ERBB4SRC | |
| SCHEMBL436188 | 0.91 | EGFR (0.75) | EGFRERBB2ERBB4SRC | |
| SCHEMBL2072074 | 0.91 | EGFR (0.75) | EGFRERBB2ERBB4SRC | |
| SCHEMBL9948680 | 0.89 | EGFR (0.80) | EGFRERBB2ERBB4HDAC3HDAC4 | |
| SCHEMBL1417948 | 0.89 | EGFR (0.67) | EGFRERBB2ERBB4HDAC3HDAC4 | |
| SCHEMBL21620272 | 0.88 | EGFR (0.68) | EGFRERBB2ERBB4HDAC3HDAC4 | |
| SCHEMBL9948576 | 0.87 | HDAC3 (0.73) | EGFRERBB2ERBB4HDAC3HDAC4 | |
| SCHEMBL15932942 | 0.86 | EGFR (0.70) | EGFRERBB2ERBB4HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185081-A1 | Bicyclic heterocylces, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-09 | — | — | US | disclosed |
| US-7223749-B2 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20050107358-A1 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107358-A1 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | RET, AR, CYP11B1 | EGFR 404/4885ERBB2 225/4885ERBB4 706/4885 |
| US-20070185081-A1 | Bicyclic heterocylces, pharmaceutical compositions containing these compounds, their use and processes for preparing them | RET, AR, RB1 | EGFR 263/4885ERBB2 140/4885ERBB4 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.